Shots:

• The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer- prior treated with 2L standard therapies. Results: ORR (45.3%); DCR (83.0%); PFS (6.9mos.); subgroup patients including patients with treated with a prior anti-HER2 regimen- ORR (43.8%) with a median treatment duration of 4.8mos.
• The ongoing P-II DESTINY-Lung01 study demonstrated that ENHERTU achieved tumor response in patients with HER2m unresectable/ mNSCLC progressed with one or more systemic therapies. Results: ORR (61.9%); DCR (90.5%); PFS (14.0 mos.)
• Both the results were presented at ASCO20. ENHERTU is a HER2-directed Ab and topoisomerase inhibitor conjugate indicated to treat patients with unresectable/ m-HER2+ breast cancer who have received 2+ prior anti-HER2-based regimens in the metastatic setting

Click here- Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca